tibodies or other substances in these presumably normal specimens. The Access PRL assay after PEG treatment may be suitable despite the CV of 14% because PEG treatment is frequently used to detect macroprolactin interference (6 ) . It is possible that two samples with low recoveries contained macroprolactin. Our experience with this assay is that samples with PEG recovery values Ͻ60% contain high-molecular-weight prolactin immunoreactivity after gel filtration.
The considerable variability seen in the Elecsys PTH and ␤-CTx and the Access GH assays after PEG treatment probably reflects interference by the PEG in the antibodyantigen reactions of these assays. Similarly, although we do not know the mechanism, it appears that HBT treatment can produce a spuriously high recovery of hormone in some assays. The manufacturers state that HBT contains a "unique blocking agent" limited to use for antigen assays to confirm or disqualify an original result in conjunction with other data (such as symptoms and other testing). Our data suggest a further limitation that its use is assay specific, possibly dependent on the assay configuration. We did not observe overrecovery in the three Elecsys assays (all configured with mouse monoclonal antibodies for both capture and detection). It was, however, apparent in the Access assays (LH, FSH, GH, and to a lesser extent, PRL), which contain solid-phase goat-antimouse monoclonal antibody complexes for capture and goat antibodies for detection.
We believe that these high HBT recovery values are likely to be spurious. The heterophile antibody interference in most immunometric assays is generally positive, leading to lower concentrations after blocking treatments, not increased values as we have mostly observed. Although 30 -40% of the population may have heterophile antibodies through exposure to animals or monoclonal antibody treatments, the frequency of interference in modern immunoassays is reported to be very low (1, 2 ) . Finally, although we did not investigate all of the specimens with HBT-induced increases in hormone concentrations, we demonstrated that the results were spurious in one case. The specimen outlier detected in the prolactin assay (Fig. 1A) and also showing overrecovery in the Access LH, FSH, and GH assays did not appear as an outlier in any Elecsys assays, or in any assay after PEG treatment. The hormone concentrations of the untreated sample were consistent with those of a "normal" 53-yearold male (7.1 IU/L LH, 12.5 IU/L FSH, 99 mIU/L PRL, and 0.02 mIU/L GH) and were within our laboratory's reference intervals. In contrast, the post-HBT values were unexpectedly high (108 IU/L LH, 37 IU/L FSH, 325 mIU/L PRL, and 1.6 mIU/L GH). Analysis by another laboratory with the Abbott Architect analyzer confirmed the untreated values (10 IU/L LH, 12 IU/L FSH, and 142 mIU/L PRL) with no increase after HBT treatment. Dilution of the untreated sample showed linearity in the Access LH, FSH, and PRL assays with dilution recoveries in the range 103-126%. In contrast, dilution of a HBTtreated aliquot showed poor linearity (170 -486%) in all assays, indicative of nonspecific interference in the assay.
In summary, the validity of the technique used to detect heterophile antibody interference is specific to each assay method. Our data suggest that use of HBT tubes may be a suitable simple technique for the Elecsys PTH, ␤-CTx, and insulin assays but not the Access LH, FSH, PRL, or GH assays. Other blocking agents may be appropriate for these methods. Pretreatment with PEG is suitable for the Elecsys insulin and Access FSH and, possibly, PRL assays. We conclude that the reagents used to test for heterophile antibody interference can themselves cause variable interference in some assay systems; therefore, the validity and expected ranges should be checked for each assay and heterophile antibody detection method. (2 ) . Genetically, there are two types of HbH disease, deletional HbH disease caused by compound heterozygosity for a double ␣-globin gene deletion on one chromosome and a single ␣-globin gene on the other (Ϫ␣/Ϫ Ϫ), and nondeletional HbH disease caused by compound heterozygosity for a double ␣-globin gene deletion and a point mutation or small deletion/insertion on a third ␣-globin
Hemoglobin
. Generally, patients with nondeletional HbH disease present with a more severe phenotype than those with deletional HbH disease (1, 2 ) .
HbH disease is particularly prevalent in Southeast Asia because of the high frequency of ␣-thalassemia carriers in these areas (1, 2 ) . In northern Thailand, ϳ1.5% (1 in 65) of babies are expected to be born with HbH disease (3 ). In addition, nondeletional HbH disease with ␣ Constant Spring (HbHCS) is very common in Thailand, where ϳ40 -50% of patients with HbH disease have nondeletional HbH with ␣ Constant Spring (4 ) . Since the 1980s, isoelectric focusing (IEF) has been widely used in the identification of hemoglobin variants and in the diagnosis of HbH disease and HbBarts hydrops fetalis because of the good separation of HbBarts, HbH, and HbCS tetramers in IEF gels. The accuracy of IEF in HbH disease classification, however, is unknown. To evaluate the accuracy of IEF in predicting ␣-globin genotype, we analyzed the genotypes of 110 Thai patients identified as having either deletional HbH disease or nondeletional HbHCS disease by IEF.
Patients were seen at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Those suspected of having thalassemia on the basis of hematologic markers were further screened by hemoglobin IEF. IEF was performed using the RESOLVE ® Hemoglobin Kit (Perkin Elmer) according to manufacturer specifications. Patients were classified as having HbH disease by IEF based on the presence of a HbH band, the farthest migrating on the IEF gel. Patients with nondeletional HbHCS were further classified by the additional presence of an HbCS band, the slow, faint migrating band before HbA2.
A single-tube multiplex gap-PCR assay was used to identify the ␣-globin gene deletions (5 ) . Samples with only one double-gene deletion were screened for point mutations in the HBA1 (␣1-globin) and HBA2 (␣2-globin) genes by direct DNA sequencing. Each gene was separately amplified by PCR with the common ␣-F forward primer and either the ␣1-R or the ␣2-R reverse primer specific to the HBA1 and HBA2 genes, respectively ( Fig. 1 ; also see Table 1 in the Data Supplement that accompanies the online version of the Technical Brief at http://www. clinchem.org/content/vol51/issue3/). Each 50-L PCR reaction contained 0.2 M each primer, 200 M each deoxynucleotide triphosphate, 1ϫ Q solution (Qiagen), and 1 U of HotStarTaq DNA polymerase in 1ϫ supplied PCR buffer (Qiagen). Thermal cycling was performed in a T3 instrument (Biometra), with an initial 15-min denaturation at 95°C, followed by 35 cycles of 98°C for 1 min, 55°C for 1 min, and 72°C for 1.5 min, with a final 5-min extension at 72°C.
We incubated 3 L of amplified product with 1 L of shrimp alkaline phosphatase (1 kU/L) and 0.4 L of exonuclease I (10 kU/L; United States Biochemical) at 37°C for 15 min to remove excess PCR primers and unincorporated deoxynucleotide triphosphates. The reaction was stopped by a 15-min incubation at 80°C.
Purified PCR products were sequenced with primers ␣-AF, ␣-BF, and ␣-R (Fig. 1 ). All three primers will anneal to both the HBA1 and HBA2 PCR products and were designed to work optimally under the same cyclesequencing condition. Each 10-L reaction mixture contained 4.4 L of purified PCR products, 1.6 L of 1 M sequencing primer, 2 L of 5ϫ Q solution (Qiagen), and 2 L of BigDye TM Terminator Ready Reaction Mix v3.0 (Applied Biosystems). An initial 2-min denaturation at 95°C was followed by 25 sequencing cycles of 98°C for 30 s, 50°C for 30 s, and 60°C for 4 min. Sequencing products were precipitated with ethanol, resuspended in 12 L of Hi-Di TM formamide, and analyzed by automated capillary electrophoresis on an ABI PRISM ® 3100 Genetic Analyzer by a rapid 40-min electrophoresis through POP-4 TM polymer across a 36-cm capillary (Applied Biosystems).
Of the 110 Thai patients identified as having HbH disease by IEF, the most common ␣-globin genotypes were Ϫ␣ 3.7 /Ϫ Ϫ SEA (n ϭ 56; 51%) and ␣ CS ␣/Ϫ Ϫ SEA (n ϭ 44; 40%). The Ϫ Ϫ SEA double-gene deletion was present in all but two patients, both of whom carried the Ϫ Ϫ THAI double-gene deletion.
Of the 67 patients identified as having deletional HbH disease by IEF, 56 were compound heterozygous Ϫ␣ 3.7 /Ϫ Ϫ SEA , 2 were Ϫ␣ 4.2 /Ϫ Ϫ SEA , 5 were ␣ CS ␣/Ϫ Ϫ SEA , 1 was ␣ Ps ␣/Ϫ Ϫ SEA , and 1 had an apparent Ϫ Ϫ SEA /Ϫ Ϫ SEA genotype, whereas the remaining 2 had an apparent ␣␣/Ϫ Ϫ SEA genotype. The IEF misclassification of the six patients with a nondeletional HbH genotype as being deletional HbH was presumably attributable to false-negative detection of the HbCS band. More surprising were the three patients in this group with A common forward primer (␣-F) is used in combination with the reverse primer ␣1-R or ␣2-R, respectively, to amplify the HBA1 and HBA2 genes. With these primers, the coding and untranslated regions as well as the promoter and some upstream sequences of each gene are amplified. Primers ␣-AF, ␣-BF, and ␣-R are used for sequencing of gene fragments of both HBA1 and HBA2. apparent Ϫ Ϫ SEA /Ϫ Ϫ SEA (one patient) and ␣␣/Ϫ Ϫ SEA (two patients) genotypes, which are inconsistent with HbH disease. However, the genotype assignments for these three patients may simply reflect the limitations of the molecular genotyping assays, which screen only for specific mutations. For example, the patient with an apparent Ϫ Ϫ SEA /Ϫ Ϫ SEA genotype could in fact be compound heterozygous for Ϫ Ϫ SEA and another deletion that is not one of the seven deletions screened for in the multiplex gap-PCR assay. If this other deletion inactivates only one ␣-globin gene, then the genotype would be entirely consistent with a HbH disease phenotype. In addition, although sequencing of the HBA1 and HBA2 genes on the nondeleted chromosome of both apparent ␣␣/Ϫ Ϫ SEA patients did not reveal any mutation that could account for their HbH disease classification, we cannot exclude the possibility that an undetected mutation exists elsewhere within the ␣-globin gene cluster in these patients. IEF is a very sensitive protein detection method, and the presence of very small amounts of HbH in ␣-thal-1 trait individuals may sometimes be misinterpreted as HbH disease. However, the red cell distribution width (RDW) in individuals with ␣-thal-1 trait is almost always within the reference interval, whereas patients with HbH disease generally have higher than normal RDW values as a result of anisocytosis. Because the two patients with an apparent ␣␣/Ϫ Ϫ SEA genotype had RDW values of 18% and 19%, which are higher than the reference interval (10.9% to 15.7%), they may actually be HbH disease patients carrying an undetected mutation in the nondeleted allele.
Among the 43 patients identified as having HbHCS disease by IEF, 39 were compound heterozygous ␣ amino acids. Thus, the migrations of the mutant HbPs and HbCS molecules in an IEF gel are likely to be very similar, if not identical, in which case the IEF assay would be unable to distinguish between them. Unfortunately, there were no significant differences in hematologic profiles between HbHPs (n ϭ 4) and HbHCS patients (n ϭ 45) to aid in differentiating between them (Table 1) .
To detect as many nondeletional ␣-thalassemia mutations as possible, we sequenced the high-GC-content ␣1-and ␣2-globin genes. Consistent with previous studies, Constant Spring was the most common nondeletional mutation (45 of 49 patients; 92%). Interestingly, the Paksé mutation was observed in four patients. Paksé was first reported in 1994 in a single Laotian patient with HbH disease (6 ) and initially thought to be rare, but there have recently been new reports of the mutation (7, 8 ) . Our findings confirm that after Constant Spring, Paksé might be the second most common nondeletional ␣-thalassemia determinant in Thailand and neighboring regions.
In summary, patients classified by IEF as being nondeletional HbH showed 100% (43 of 43) concordance with molecular genotyping results, although IEF could not distinguish between types of point mutations and doublegene deletions. Molecular genotyping results for patients classified by IEF as having deletional HbH, however, were only 87% (58 of 67) concordant because of misclassification of several HbHCS, HbHPs, apparently homozygous Ϫ Ϫ SEA , and apparently heterozygous Ϫ Ϫ SEA patients as having deletional HbH. Overall, the majority of these discrepancies are not anticipated to pose a major problem in patient management, given the broad and overlapping hematologic profiles of deletional and nondeletional HbH disease (Table 1) . However, the true prevalences of various deletional and nondeletional ␣-thalassemia determinants is masked. Molecular diagnosis is still necessary for accurate ␣-thalassemia genotyping, confirmation of clinical/hematologic diagnoses of ␣-thalassemia, and prenatal counseling and diagnosis/ prevention of severe ␣-thalassemia in at-risk pregnancies. Table 1 . Hematologic profiles of patients with deletional and nondeletional HbH disease, HbH Paksé, and HbHCS. Mitochondrial fatty acid oxidation (FAO) represents a normal metabolic response to increased energy demands during periods of fasting, febrile illness, or muscular exertion. FAO is a complex pathway involving activation of free fatty acids to acyl-CoA species, transport into mitochondria, and cyclic oxidation to break the longchain fatty acids into acetyl-CoA and a two-carbon chainshortened acyl-CoA, which is then recycled. Acetyl-CoA is used in the Krebs cycle and in liver as a substrate for ketogenesis (1 ) (2, 3 ) . Palmitic acid (C16) is used to detect long-chain defects, including deficiencies in very long chain acyl-CoA dehydrogenase, long-chain l-3-hydroxy acyl-CoA dehydrogenase, long-chain 3-keto acyl-CoA thiolase, carnitine/acylcarnitine translocase, carnitine pamitoyltransferase 1, and carnitine pamitoyltransferase 2. Myristic acid (C14) is used to detect defects in mediumchain FAO, such as medium-chain acyl-CoA dehydrogenase deficiency. We use tritiated fatty acids labeled in the (9,10) position. The assay will not detect defects in carnitine palmitoyl transferase 1B; short-chain FAO defects, including short-chain acyl-CoA dehydrogenase and short-chain l-3-hydroxy acyl-CoA dehydrogenase; and short-chain-3-keto acyl-CoA thiolase deficiencies.
Historically, patient samples have been compared with batch controls, and a reference interval was not established for this assay. In the present study we have assigned a reference interval for the assay, using FAO flux results from triplicate assays performed on 1000 fibroblast samples. These samples were derived from individuals with clinical signs indicating impaired energy metabolism but with apparently normal FAO compared with data obtained from patients with well-characterized, genetically confirmed FAO defects. Assigning a reference interval is critical for a clinically reportable assay because it simplifies the interpretation of the results and provides a clear definition of disease vs nondisease.
The FAO flux assay consists of measurement of FAO flux in fibroblasts obtained from one T-25 flask for each patient, typically with fewer than eight passages of culture. Fibroblasts are trypsinized and resuspended in 12-36 mL of DMEM (cat. no. 11885-084; Gibco Life Technologies) containing 1 g/L glucose and supplemented with 100 mL/L fetal calf serum (cat. no. 26140-053; Gibco Life Technologies). From this suspension, 1 mL is transferred to 2 wells in each of five 24-well tissue culture plates. Three nondisease control fibroblast and two disease control fibroblast lines are simultaneously seeded in the same plate along with one to six additional patient lines. Cultures are placed in an incubator to allow the fibroblasts to attach and then grow for 48 h at 37°C, in 5% CO 2 , 100% humidity (CO 2 Incubator; NUAIRE). The cells are then washed with phosphate-buffered saline (pH 6.9) and incubated with preincubation medium (Krebs Ringer Bicarbonate Medium; cat. no. K-4002; Sigma) containing 0.5 g/L bovine serum albumin (fatty-acid free, cat. no. A-6003; Sigma) in the assay plates or with inhibitor medium [preincubation medium ϩ FAO inhibitors consisting of 0.45 mmol/L malonyl-CoA (cat. no. M-4263; Sigma), 0.02 mmol/L glybenclamide (cat. no. G-0639; Sigma), 0.79 mmol/L 3-mercaptoproprionic acid (cat. no. M-6750; Sigma), and 2.74 mmol/L glucose (cat. no. G-5767; Sigma) in a buffer containing 1.0 g/L bovine
